GlobeNewswire

Klövern issues green bonds of SEK 2,500 million and announces results from tender offer for the outstanding 2018/2021 SEK bonds

Share

This press release should be read in conjunction with the press release published by the Issuer on 29 January 2021 at 10:00 CET and the related Tender Information Document.

No offer or invitation to acquire or sell any securities is being made pursuant to this announcement.

NOT FOR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED) OR IN ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT. THE DISTRIBUTION OF THIS DOCUMENT IN CERTAIN JURISDICTIONS (IN PARTICULAR, THE UNITED STATES AND THE UNITED KINGDOM) MAY BE RESTRICTED BY LAW.

Bond issue

Klövern AB (publ) (the “Issuer” or “Klövern”) has successfully issued senior unsecured green bonds in the total amount of SEK 2,500 million under the Issuer’s MTN programme. The bonds have a tenor of 4 years and a floating interest rate of STIBOR three months plus 325 bps and will mature on 10 February 2025 (the “New Bonds”). Klövern intends to apply for listing of the New Bonds on the sustainable bond list of Nasdaq Stockholm.

The Tender Offer

Klövern further announces the results of the tender offer (the "Tender Offer") to the holders of Klövern's outstanding senior unsecured floating rate bonds maturing on 26 February 2021 with ISIN SE0010831198 and outstanding amount of SEK 1,500 million (the “Bonds”). The Tender Offer expired at 12:00 CET on 3 February 2021. The Tender Offer has been accepted by holders of Bonds representing a total nominal amount of SEK 1,185 million1.

Klövern will complete the Tender Offer and accepts all tendered Bonds for purchase. The price for the Bonds in the Tender Offer amounts to 100.20 per cent of the nominal amount. Klövern will also pay accrued and unpaid interest from, but excluding, the previous interest payment date until, and including, the settlement date. Settlement date for the Tender Offer is expected to occur on 10 February 2021.

Settlement of the transactions pursuant to the Tender Offer will occur as a secondary trade via Danske Bank A/S, Danmark, Sverige Filial, Nordea Bank Abp, Nykredit Bank A/S and Swedbank AB (publ)  (the “Dealer Managers”). All tendering Bondholders should coordinate the trade bookings with their local sales representative immediately.

Information about the Tender Offer may be obtained from the Dealer Managers.

Danske Bank A/S, Danmark, Sverige Filial: +45 3051 5941, dcm_sweden@danskebank.se
Nordea Bank Abp: +45 6161 2996, NordeaLiabilityManagement@nordea.com
Nykredit Bank A/S: +45 40498228, liabilitymanagement@nykredit.dk
Swedbank AB (publ): +46 8 700 90 22, Syndicate@swedbank.se

Klövern AB (publ)

For further information, please contact:
Jens Andersson, Head of Finance, +46 76 855 67 02, jens.andersson@klovern.se

Klövern is a real estate company committed to working closely with customers to offer them attractive premises in growth regions. Klövern is listed on Nasdaq Stockholm. For further information, see www.klovern.se.

Klövern AB (publ), Bredgränd 4, 111 30 Stockholm. Phone: +46 10 482 70 00. E-mail: info@klovern.se.

This is a translation of the original Swedish language press release. In the event of discrepancies, the original Swedish wording shall prevail.

[1] SEK 200,000,000 has previously been repurchased, but not cancelled, by the Issuer.

Attachment


About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Norsk Hydro: Invitation to Investor presentation - Hydro agrees to sell Rolling business area to KPS Capital Partners5.3.2021 07:31:00 CETPress release

President & CEO, Hilde Merete Aasheim, will present the transaction by an audio webcast and a conference call, in English, at 09:00 CET today, Friday 5 March. In order to listen to the presentation, please join the audio webcast. There will be a Q&A session directly after the presentation. If you would like to ask questions, you need to join the conference call before end of the presentation. Please see details below. It will not be possible to ask questions on the audio webcast. To join the conference call, please use the below “Click to Join” link 5-10 minutes prior to start time. You will be asked to enter your phone number and registration details. The Event Conferencing system will call you on the phone number you provide and place you into the event. Please note that the “Click to Join” link becomes active 15 minutes prior to the scheduled start time. Please use the “Click to Join” option for the easiest way to join the conference call. Click to Join Call 09:00 CET >> As an alter

Norsk Hydro: Invitasjon til Investorpresentasjon - Hydro selger forretningsområdet Rolling til KPS Capital Partners5.3.2021 07:31:00 CETPressemelding

Konsernsjef Hilde Merete Aasheim vil presentere transaksjonen i dag, fredag 5. mars kl. 09.00 (norsk tid) via audio webcast og telefonkonferanse. Presentasjonen kan følges via audio webcast. Det vil være mulig å stille spørsmål rett etter presentasjonen. For å stille spørsmål må du være koblet på telefonkonferansen før presentasjonen er ferdig. Se detaljer nedenfor. Det vil ikke være mulig å stille spørsmål via audio webcast. Du melder deg på telefonkonferansen ved å klikke på lenken “Click to Join“ 5-10 minutter før start. Du må oppgi telefonnummer og registreringsdetaljer. Konferansesystemet vil ringe tilbake på det oppgitte telefonnummeret og koble deg til konferansen. “Click to Join“-lenken vil være aktiv fra 15 minutter før planlagt start. Vennligst bruk “Click to Join“ for den enkleste måten å delta på telefonkonferansen. Click to Join Call 09:00 CET >> Alternativt kan du ringe numrene nedenfor for telefonkonferansen: Norge +47 2100 2613 UK +44 (0)330 336 9104 USA +1 323-794-2442

Norsk Hydro: Hydro agrees to sell Rolling business area to KPS Capital Partners for EUR 1,380 million5.3.2021 07:30:00 CETPress release

Energy and aluminium company Norsk Hydro ASA has entered into an agreement to sell its Rolling business to KPS Capital Partners for EUR 1,380 million on an enterprise value basis. A major step on Hydro's agenda to improve profitability and drive sustainability. The transaction includes seven plants, one R&D center, global sales offices, and around 5,000 employees of which 650 employees in Norway and the remaining mainly in Germany. “Hydro launched a strategic review of our Rolling business area in 2019, along with other strategic measures towards profitability and sustainability. We have now concluded, and our Rolling business will continue its development under new ownership. This is a good solution for both Hydro and for the employees in Rolling, who will continue their efforts and continued growth in a new, dedicated downstream company,” says Hydro President and CEO Hilde Merete Aasheim. “Hydro’s ambition is to lift profitability and drive sustainability, creating value for all stak

Norsk Hydro: Hydro selger forretningsområdet Rolling til KPS Capital Partners for 1.380 millioner euro5.3.2021 07:30:00 CETPressemelding

Energi- og aluminiumselskapet Norsk Hydro ASA har inngått en avtale om å selge forretningsområdet Rolling til KPS Capital Partners for 1.380 millioner euro Enterprise Value. Dette er et stort skritt videre for Hydros agenda om å løfte lønnsomheten og fremme bærekraft. Transaksjonen omfatter syv anlegg, ett FoU-senter og internasjonale salgskontorer, i tillegg til rundt 5 000 ansatte hvorav 650 i Norge og resterende hovedsakelig i Tyskland. – Hydro startet en strategisk gjennomgang av forretningsområdet Rolling i 2019, sammen med andre strategiske tiltak for økt lønnsomhet og bærekraft. Vi har nå konkludert, og forretningsområdet Rolling vil fortsette sin utvikling under nytt eierskap. Dette er en god løsning, både for Hydro og for de ansatte i Rolling, som vil fortsette arbeidet og vokse videre i et nytt, rendyrket nedstrømselskap, sier Hydros konsernsjef, Hilde Merete Aasheim. – Hydros ambisjon er å løfte lønnsomheten og fremme bærekraft, og skape verdier for alle interessegrupper. Sa

Heijmans and AM join forces in Feyenoord City Rotterdam5.3.2021 07:30:00 CETPress release

Heijmans and project developer AM have joined forces in the Feyenoord City development consortium, which aims to develop and realise homes and commercial and social amenities in Rotterdam South. This collaboration is a significant step towards the integrated development of the area. Homes and commercial real estate The Heijmans-AM consortium will be working closely with Stigam (Stichting Gebiedsontwikkeling aan de Maas – the foundation set up to oversee the area development). Stigam is responsible for the land development. The Rotterdam South area development entered a new phase following the Rotterdam city council’s adoption of the zoning plan in late 2020. Feyenoord City will include the new stadium that will be developed by Stadion Feijenoord N.V. Around this new stadium, the Heijmans-AM consortium will develop an attractive city district that will include homes, a hotel, food & beverage outlets and shops. The Feyenoord City Masterplan gives the room to develop a total of around 3,7

ObsEva Announces Year End 2020 Financial Results and Business Update5.3.2021 07:00:00 CETPress release

-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept- -Actively pursuing new indications and partnerships to maximize value of pipeline candidates- GENEVA, Switzerland and BOSTON, MA – March 5, 2021 – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today reported financial results for the year ended December 31, 2020 and provided a business update. “2020 was a critical year for ObsEva as it marked the beginning of our transformation from a clinical stage company to one preparing for regulatory approvals and commercialization,” said Brian O’Callaghan, CEO of ObsEva. “The clinical and regulatory achievements of 2

Roche’s Actemra/RoActemra becomes the first biologic therapy approved by the FDA for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease, a rare, debilitating condition5.3.2021 07:00:00 CETPress release

Systemic sclerosis (SSc) is a rare disease that affects about 2.5 million people worldwide Approximately 80% of SSc patients may be affected by interstitial lung disease (ILD), a progressive disease that can significantly impact lung function and can be life-threateningIn a global study, Actemra/RoActemra reduced the rate of progressive loss of lung function in people with SSc-ILD compared to placeboThe U.S. Food and Drug Administration previously granted Priority Review designation to Actemra/RoActemra for the treatment of SSc-ILD Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), a debilitating condition with limited treatment options. Actemra/RoActemra is the first biologic therapy approved by the FDA for